Inovio Pharmaceuticals, Inc.
INO
NASDAQ·Healthcare·Biotechnology·Mkt cap $98.8M
$1.43
▲ +5.15%
P/E
-1.23
Mkt Cap
$98.8M
52-Wk Range
$0.56–$2.98
52-Week Range
$0.56 - $2.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 50.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary SynCon DNA sequence optimization technology enabling rapid, precise vaccine design
- CELLECTRA smart device delivery system providing superior cellular uptake compared to traditional methods
- Diversified pipeline across high-unmet-need oncology and infectious disease markets
- Strategic partnerships with government agencies (DoD, NIH, DARPA) and pharmaceutical leaders (AstraZeneca, Regeneron) validating platform
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Phase 2/3 clinical trial progression for HPV-associated cancer and infectious disease candidates with multiple near-term readouts
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+33.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 12, 2026
Reported EPS of -$0.07 vs -$0.22 consensus (+67.7% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+67.7%
Revenue trend · last 8Q
—
—
—
-100%
—
-100%
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$117.0K
$65.3K
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 13, 2026
vs Industry
How INO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related